Shamrock Industrial Past Earnings Performance
Past criteria checks 0/6
Shamrock Industrial has been growing earnings at an average annual rate of 28.8%, while the Pharmaceuticals industry saw earnings growing at 14.2% annually. Revenues have been growing at an average rate of 59.1% per year.
Key information
28.8%
Earnings growth rate
25.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 59.1% |
| Return on equity | -2.5% |
| Net Margin | -39.6% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Shamrock Industrial makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 1 | 0 | 0 | 0 |
| 30 Sep 23 | 1 | 0 | 0 | 0 |
| 30 Jun 23 | 0 | -1 | 0 | 0 |
| 31 Mar 23 | 0 | -1 | 0 | 0 |
| 31 Dec 22 | 0 | -2 | 0 | 0 |
| 30 Sep 22 | 1 | -1 | 0 | 0 |
| 30 Jun 22 | 1 | -1 | 0 | 0 |
| 31 Mar 22 | 1 | -2 | 0 | 0 |
| 31 Dec 21 | 1 | -3 | 0 | 0 |
| 30 Sep 21 | 0 | -4 | 0 | 0 |
| 30 Jun 21 | 0 | -4 | 0 | 0 |
| 31 Mar 21 | 0 | -3 | 0 | 0 |
| 31 Dec 20 | 0 | -2 | 0 | 0 |
| 30 Sep 20 | 0 | -2 | 0 | 0 |
| 30 Jun 20 | 0 | -2 | 0 | 0 |
| 31 Mar 20 | 0 | -2 | 0 | 0 |
| 31 Dec 19 | 0 | -67 | 0 | 0 |
| 30 Sep 19 | 0 | -67 | 1 | 0 |
| 30 Jun 19 | 0 | -67 | 1 | 0 |
| 31 Mar 19 | 0 | -3 | 1 | 0 |
| 31 Dec 18 | 0 | 62 | 1 | 0 |
| 30 Sep 18 | 0 | 62 | 1 | 0 |
| 30 Jun 18 | 0 | 62 | 1 | 0 |
| 31 Mar 18 | 0 | -1 | 0 | 0 |
| 31 Dec 17 | 0 | 0 | 0 | 0 |
| 30 Sep 17 | 0 | 0 | 0 | 0 |
| 30 Jun 17 | 0 | 0 | 0 | 0 |
| 31 Mar 17 | 0 | -1 | 0 | 0 |
| 31 Dec 16 | 0 | -20 | 0 | 0 |
| 30 Sep 16 | 0 | -20 | 0 | 0 |
| 30 Jun 16 | 0 | -20 | 0 | 0 |
| 31 Mar 16 | 0 | -20 | 0 | 0 |
| 31 Dec 15 | 0 | 0 | 0 | 0 |
| 30 Sep 15 | 0 | 0 | 0 | 0 |
| 30 Jun 15 | 0 | 0 | 0 | 0 |
| 31 Mar 15 | 0 | 0 | 0 | 0 |
| 31 Dec 14 | 0 | 0 | 0 | 0 |
| 30 Sep 14 | 0 | 0 | 0 | 0 |
| 30 Jun 14 | 0 | 0 | 0 | 0 |
| 31 Mar 14 | 0 | 0 | 0 | 0 |
| 31 Dec 13 | 0 | 0 | 0 | 0 |
| 30 Sep 13 | 0 | 0 | 0 | 0 |
Quality Earnings: 531240 is currently unprofitable.
Growing Profit Margin: 531240 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 531240 is unprofitable, but has reduced losses over the past 5 years at a rate of 28.8% per year.
Accelerating Growth: Unable to compare 531240's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 531240 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (23.1%).
Return on Equity
High ROE: 531240 has a negative Return on Equity (-2.46%), as it is currently unprofitable.